These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

189 related items for PubMed ID: 17356528

  • 1. Impact of weight loss on the metabolic syndrome.
    Phelan S, Wadden TA, Berkowitz RI, Sarwer DB, Womble LG, Cato RK, Rothman R.
    Int J Obes (Lond); 2007 Sep; 31(9):1442-8. PubMed ID: 17356528
    [Abstract] [Full Text] [Related]

  • 2. Effect of hypocaloric diet plus sibutramine treatment on hormonal and metabolic features in overweight and obese women with polycystic ovary syndrome: a randomized, 24-week study.
    Florakis D, Diamanti-Kandarakis E, Katsikis I, Nassis GP, Karkanaki A, Georgopoulos N, Panidis D.
    Int J Obes (Lond); 2008 Apr; 32(4):692-9. PubMed ID: 18071341
    [Abstract] [Full Text] [Related]

  • 3. Effects of sibutramine plus orlistat in obese women following 1 year of treatment by sibutramine alone: a placebo-controlled trial.
    Wadden TA, Berkowitz RI, Womble LG, Sarwer DB, Arnold ME, Steinberg CM.
    Obes Res; 2000 Sep; 8(6):431-7. PubMed ID: 11011909
    [Abstract] [Full Text] [Related]

  • 4. Use of sibutramine to assist obese women with weight loss can be successful in dietitian-led clinics: another tool in the dietitian's toolbox.
    Barratt R, Frost G, O'Boyle A, Millward J, Truby H.
    J Hum Nutr Diet; 2008 Jun; 21(3):248-55. PubMed ID: 18477180
    [Abstract] [Full Text] [Related]

  • 5. Weight loss and quality of life improvement in obese subjects treated with sibutramine: a double-blind randomized multicenter study.
    Di Francesco V, Sacco T, Zamboni M, Bissoli L, Zoico E, Mazzali G, Minniti A, Salanitri T, Cancelli F, Bosello O.
    Ann Nutr Metab; 2007 Jun; 51(1):75-81. PubMed ID: 17356258
    [Abstract] [Full Text] [Related]

  • 6. Use of sibutramine in obese mexican adolescents: a 6-month, randomized, double-blind, placebo-controlled, parallel-group trial.
    García-Morales LM, Berber A, Macias-Lara CC, Lucio-Ortiz C, Del-Rio-Navarro BE, Dorantes-Alvárez LM.
    Clin Ther; 2006 May; 28(5):770-82. PubMed ID: 16861099
    [Abstract] [Full Text] [Related]

  • 7. Effects of lifestyle intervention and metformin on weight management and markers of metabolic syndrome in obese adolescents.
    Harden KA, Cowan PA, Velasquez-Mieyer P, Patton SB.
    J Am Acad Nurse Pract; 2007 Jul; 19(7):368-77. PubMed ID: 17680902
    [Abstract] [Full Text] [Related]

  • 8. Sibutramine plus meal replacement therapy for body weight loss and maintenance in obese patients.
    Early JL, Apovian CM, Aronne LJ, Fernstrom MH, Frank A, Greenway FL, Heber D, Kushner RF, Cwik KM, Walch JK, Hewkin AC, Blakesley V.
    Obesity (Silver Spring); 2007 Jun; 15(6):1464-72. PubMed ID: 17557984
    [Abstract] [Full Text] [Related]

  • 9. Effects of sibutramine-induced weight loss on cardiovascular system in obese subjects.
    de Simone G, Romano C, De Caprio C, Contaldo F, Salanitri T, di Luzio Paparatti U, Pasanisi F.
    Nutr Metab Cardiovasc Dis; 2005 Feb; 15(1):24-30. PubMed ID: 15871847
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Acute effect of weight loss on levels of total bilirubin in obese, cardiovascular high-risk patients: an analysis from the lead-in period of the Sibutramine Cardiovascular Outcome trial.
    Andersson C, Weeke P, Fosbøl EL, Brendorp B, Køber L, Coutinho W, Sharma AM, Van Gaal L, Finer N, James WP, Caterson ID, Rode RA, Torp-Pedersen C, SCOUT Executive Steering Committee, SCOUT investigators.
    Metabolism; 2009 Aug; 58(8):1109-15. PubMed ID: 19454355
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. The effect of sibutramine-assisted weight loss in men with obstructive sleep apnoea.
    Yee BJ, Phillips CL, Banerjee D, Caterson I, Hedner JA, Grunstein RR.
    Int J Obes (Lond); 2007 Jan; 31(1):161-8. PubMed ID: 16652122
    [Abstract] [Full Text] [Related]

  • 15. Blood pressure changes associated with sibutramine and weight management - an analysis from the 6-week lead-in period of the sibutramine cardiovascular outcomes trial (SCOUT).
    Sharma AM, Caterson ID, Coutinho W, Finer N, Van Gaal L, Maggioni AP, Torp-Pedersen C, Bacher HP, Shepherd GM, James WP, SCOUT Investigators.
    Diabetes Obes Metab; 2009 Mar; 11(3):239-50. PubMed ID: 18671798
    [Abstract] [Full Text] [Related]

  • 16. The obese older female patient: CV risk and the SCOUT study.
    Coutinho WF.
    Int J Obes (Lond); 2007 Nov; 31 Suppl 2():S26-30; discussion S31-2. PubMed ID: 17968434
    [Abstract] [Full Text] [Related]

  • 17. Prediction of response to sibutramine therapy in obese non-diabetic and diabetic patients.
    Finer N, Ryan DH, Renz CL, Hewkin AC.
    Diabetes Obes Metab; 2006 Mar; 8(2):206-13. PubMed ID: 16448525
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Effects of sibutramine in overweight, poorly controlled Chinese female type 2 diabetic patients: a randomised, double-blind, placebo-controlled study.
    Wang TF, Pei D, Li JC, Tsai WC, Tsai CC, Yao CY, Chang ET, Hsieh MC, Su KY, Kuo SW.
    Int J Clin Pract; 2005 Jul; 59(7):746-50. PubMed ID: 15963197
    [Abstract] [Full Text] [Related]

  • 20. Psychobehavioral and nutritional predictors of weight loss in obese women treated with sibutramine.
    Hainer V, Kunesova M, Bellisle F, Hill M, Braunerova R, Wagenknecht M.
    Int J Obes (Lond); 2005 Feb; 29(2):208-16. PubMed ID: 15583700
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.